Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

PILOT STUDY PHASE II, Multicenter, Non-randomized, TO ASSESS THE EFFICACY AND SAFETY OF LENALIDOMIDE IN INDUCTION AND POST-INDUCTION IN PATIENTS WITH NOVO Acute Myeloid Leukemia (AML) WITH Cytogenetic Abnormality Monosomy 5

NCT01198054 is registered in ClinicalTrials.gov with PETHEMA Foundation as lead sponsor.

NCT NCT01198054
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01198054 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
PILOT STUDY PHASE II, Multicenter, Non-randomized, TO ASSESS THE EFFICACY AND SAFETY OF LENALIDOMIDE IN INDUCTION AND POST-INDUCTION IN PATIENTS WITH NOVO Acute Myeloid Leukemia (AML) WITH Cytogenetic Abnormality Monosomy 5
Lead sponsor
PETHEMA Foundation
Phase
Phase 4
Overall status
Terminated
Start date
January 31, 2011
Completion date
February 28, 2013
Enrollment
4 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

aml